Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asciminib as a third line option in chronic myeloid leukemia.

International journal of hematology - 1 Jan 2023

Laganà Alessandro, Scalzulli Emilia, Carmosino Ida, Martelli Maurizio, Breccia Massimo

Abstract excerpt

Unmet needs remain in the treatment of chronic phase chronic myeloid leukemia (CML) in later lines. Sequential use of tyrosine kinase inhibitors (TKIs) is associated with decreased overall survival and emergence of new mutations, particularly the T315I mutation. Among the new drugs developed to overcome resistance and intolerance, the STAMP inhibitor asciminib (which specifically targets the ABL myristoyl pocket)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Source

Identifiers

PMID: 35930119
DOI: 10.1007/s12185-022-03432-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asciminib as a third line option in chronic myeloid leukemia.PMID 35930119Read ↗

Asciminib for chronic myeloid leukaemia: Next questions.Semantic proximity Read ↗

Asciminib in the treatment of chronic myeloid leukemia in chronic phase.Semantic proximity Read ↗

Asciminib in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 TrialSemantic proximity Read ↗

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.Semantic proximity Read ↗

Advances of next-generation STAMP inhibitors in chronic myeloid leukemia.Semantic proximity Read ↗

Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.Semantic proximity Read ↗

Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.Semantic proximity Read ↗

Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.Semantic proximity Read ↗

[Recent advances in the treatment of chronic myeloid leukemia].Semantic proximity Read ↗

Genetic Landscape of Chronic Myeloid Leukemia and a Novel Targeted Drug for Overcoming Resistance.Semantic proximity Read ↗

Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.